Suppr超能文献

肝移植中不同再灌注顺序的短期和长期结果

Short- and Long-Term Outcomes of Different Reperfusion Sequences in Liver Transplantation.

作者信息

Eichelmann Ann-Kathrin, Vogel Thomas, Fuchs Ann-Kathrin, Houben Philipp, Katou Shadi, Becker Felix, Schmidt Hartmut H, Wilms Christian, Pascher Andreas, Brockmann Jens G

机构信息

Department of General, Visceral and Transplant Surgery, University Hospital of Münster, Münster, Germany.

Department of Gastroenterology/Hepatology, University Hospital of Münster, Münster, Germany.

出版信息

Ann Transplant. 2021 Feb 19;26:e926847. doi: 10.12659/AOT.926847.

Abstract

BACKGROUND Although most centers perform primary portal vein reperfusion (PV) in orthotopic liver transplantation (OLT) for historical reasons, there is so far no sound evidence as to whether this technique is superior. The present study evaluated the long-term outcome of 3 different reperfusion sequences: PV vs primary arterial (A) vs simultaneous reperfusion (SIM). MATERIAL AND METHODS All patients at our center who underwent OLT (who received a primary, whole-organ liver graft) from 2006 to 2007 were evaluated for analysis. RESULTS A total of 61 patients were found eligible (PV: 25, A: 22, SIM: 14). Twenty-one patients (35%) were still alive after the follow-up period of 12 years. Despite poorer starting conditions such as higher recipient age (59 y (SIM) vs 55 y (A) vs 50 y (PV), P=0.01) and donor age (56 y (SIM) vs 51 y (PV) vs 50 y (A), n.s.), higher MELD scores (22 vs 19 (PV) vs 17 (A), n.s.), as well as a higher number of marginal donor organs (79% (SIM) vs 36% (A/PV), P=0.02), SIM-recipients demonstrated superior outcomes. Overall survival was 8.1 y (SIM), 4.8 y (PV), and 5.9 y (A, n.s.)). None of the SIM-recipients underwent re-transplantation, while the rate was 32% in the PV-group. The 8.1 y graft survival in SIM-recipients was significantly longer than in the other 2 groups, which were 3.3 y (PV) and 5.5 y (A, P=0.013). CONCLUSIONS Although SIM-reperfused recipients were the oldest and received grafts of inferior quality, these recipients showed superior results in terms of overall patient and graft survival. Multicentric randomized controlled trials with larger study populations are required to confirm this finding.

摘要

背景

由于历史原因,大多数中心在原位肝移植(OLT)中进行门静脉一期再灌注(PV),但迄今为止,尚无充分证据表明该技术是否更具优势。本研究评估了三种不同再灌注顺序的长期结果:PV与动脉一期再灌注(A)与同步再灌注(SIM)。

材料与方法

对2006年至2007年在本中心接受OLT(接受整块全器官肝移植)的所有患者进行评估以进行分析。

结果

共发现61例符合条件的患者(PV组:25例,A组:22例,SIM组:14例)。在12年的随访期后,21例患者(35%)仍存活。尽管起始条件较差,如受者年龄较大(SIM组为59岁,A组为55岁,PV组为50岁,P=0.01)、供者年龄较大(SIM组为56岁,PV组为51岁,A组为50岁,无统计学意义)、终末期肝病模型(MELD)评分较高(SIM组为22分,PV组为19分,A组为17分,无统计学意义)以及边缘供肝数量较多(SIM组为79%,A/PV组为36%,P=0.02),但SIM组受者的结局更好。总体生存率分别为:SIM组8.1年,PV组4.8年,A组5.9年(无统计学意义)。SIM组受者均未接受再次移植,而PV组的再次移植率为32%。SIM组受者8.1年的移植物生存率显著长于其他两组,PV组为3.3年,A组为5.5年(P=0.013)。

结论

尽管接受SIM再灌注的受者年龄最大且接受的移植物质量较差,但这些受者在患者总体生存率和移植物生存率方面表现出更好的结果。需要进行更大样本量的多中心随机对照试验来证实这一发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad18/7901155/617f781fb433/anntransplant-26-e926847-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验